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Abstract
Background: Troponin I (TnI) is frequently elevated in critical illness, but its interpretation is unclear. Our primary
objectives in this study were to evaluate whether TnI is associated with hospital mortality and if this association
persists after adjusting for potential confounders. We also aimed to ascertain whether addition of TnI to the Acute
Physiological and Chronic Health Evaluation II (APACHE II) risk prediction model improves its performance in
general intensive care unit (ICU) populations.
Methods: We performed an observational cohort study with independent derivation and validation cohorts in two
general level 3 ICU departments in the United Kingdom. The derivation cohort was a 4.5-year cohort (2010–2014) of
general ICU index admissions (n = 1349). The validation cohort was used for secondary analysis of a prospective
study dataset (2010) (n = 145). The primary exposure was plasma TnI concentration taken within 24 h of ICU admission.
The primary outcome was hospital mortality. We performed multivariate regression, adjusting for components of the
APACHE II model. We derived the risk prediction score from the multivariable model with TnI.
Results: Hospital mortality was 37.3% (n = 242) for patients with detectable TnI, compared with 14.6% (n = 102) for
patients without detectable TnI. There was a significant univariate association between TnI and hospital mortality
(OR per doubling TnI 1.16, 95% CI 1.13–1.20, p < 0.001). This persisted after adjustment for APACHE II model components
(TnI OR 1.05, 95% CI 1.01–1.09, p = 0.003). TnI correlated most strongly with the acute physiology score (APS) component
of APACHE II (r = 0.39). Addition of TnI to the APACHE II model did not improve discrimination (APACHE II concordance
statistic [c-index] 0.835, 95% CI 0.811–0.858; APACHE II + TnI c-index 0.837, 95% CI 0.813–0.860; p = 0.330) or other
measures of model performance.
Conclusions: TnI is an independent predictor of hospital mortality and correlates most highly with the APS component
of APACHE II. It does not improve risk prediction. We would not advocate the adoption of routine troponin analysis on
admission to ICU, and we recommend that troponin be measured only if clinically indicated.
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Background
Troponin is used routinely in combination with clinical
signs, symptoms and electrocardiography to diagnose or
rule out myocardial infarction (MI) [1], and also as a
prognostic marker in pulmonary embolism [2]. In crit-
ical illness, troponin is frequently elevated, but its inter-
pretation in this context is uncertain. Researchers in
several studies of intensive care unit (ICU) and high-risk
surgical populations have described significant crude as-
sociations between troponin elevation and increased
hospital and longer-term mortality [3–5]. There has
been increasing interest in the use of troponin in risk
stratification in major non-cardiac surgery. In the Vascu-
lar Events in Noncardiac Surgery Patients Cohort Evalu-
ation (VISION) study, investigators recently found that
peak post-operative troponin T (TnT) was significantly
associated with 30-day mortality after adjustment for pa-
tient characteristics, and type of surgery [6]. However,
the mechanism of a causal association between troponin
elevation and mortality is uncertain. Specifically, the aeti-
ology of troponin release is likely multifactorial, and the
relative importance of inflammatory and ischaemic myo-
cardial injury is uncertain. In addition, there is conflicting
evidence regarding whether troponin is an independent
predictor of hospital mortality after adjustment or stratifi-
cation for severity of illness in critically ill patients [7–10].
The use of multivariable risk prediction models which
include diagnosis, severity of illness and other patient
characteristics is standard in intensive care and enables
benchmarking of practice and outcomes across units
[11]. The Scottish Intensive Care Society Audit Group
(SICSAG) uses the Acute Physiological and Chronic
Health Evaluation II (APACHE II) model [12], which
combines acute physiological derangement and present-
ing diagnosis with chronic health status and age. It has
been validated and recalibrated using Scottish data [13].
Addition of new variables may improve the accuracy of
existing models; for example, the UK Intensive Care Na-
tional Audit and Research Centre recently improved the
accuracy and discrimination of its model by including
lactate [14]. The strong univariate association of tropo-
nin with mortality makes it an ideal candidate predictor
variable to assess in current risk prediction models.
In the present study, we aimed to explore the possible
independent relationship between early troponin I (TnI)
and hospital mortality in ICU patients. We explored uni-
variate associations between early TnI concentration and
mortality. We then explored how this relationship was
modified by adjustment for potential confounding vari-
ables that predict death during the first 24 h of ICU
admission. Finally, we investigated whether the addition
of TnI to the existing APACHE II risk prediction model
improves its performance as a predictor of hospital mor-
tality in general critical care populations.
Methods
Data sources and participants
Two prospectively collected datasets were available with
routine TnI measurement in ICU patients from two
distinct ICUs. Glasgow Royal Infirmary (GRI), Scotland,
collected TnI samples on all patients admitted to ICU
three times each week (on Mondays, Wednesdays and
Fridays) from 1 January 2010 through 30 June 2014.
These measurements were supplemented by clinically
indicated TnI measurements at clinician discretion
(Glasgow dataset). Ostermann et al. also performed rou-
tine TnI measurement (in addition to their published
TnT) within 24 h of ICU admission to a large London
ICU (St Thomas’ hospital) for all patients recruited to
an observational study to investigate the impact of serial
troponin measurements on the diagnosis of MI and hos-
pital and 6-month mortality in patients admitted to ICU
with non-cardiac diagnoses (London dataset) [3].
For the Glasgow dataset, we linked TnI data; clinical
data extracted from the hospital clinical information sys-
tem (CareVue®; Koninklijke Philips Electronics N.V.,
Eindhoven, The Netherlands); and routinely collected,
administratively linked registry data derived from the
SICSAG [15], Scottish Morbidity Record of acute hos-
pital admissions (SMR01) and Scottish death records.
All data were anonymised prior to release to the re-
searchers, and therefore an ethics waiver was granted by
the local research ethics committee (West of Scotland
Research Ethics Service), and approvals from NHS
Greater Glasgow and Clyde Caldicott Guardian and SIC-
SAG were obtained.
Methods for the London dataset are described else-
where [3]. TnI measurements were part of the original
protocol and were reported in a subsequent publication
[16]. Data were anonymised prior to release to the re-
searchers. We restricted the dataset to patients in whom
TnI measurements were taken in the first 24 h of ICU
admission. All diagnoses were recorded as free text,
which we mapped to APACHE II diagnosis categories.
Variables
The primary outcome was hospital mortality. The primary
predictor was TnI. We entered TnI as a continuous va-
riable. We assessed linearity of TnI using fractional poly-
nomials and identified that a logarithmic transformation
of TnI best represented the data. We used a base 2 loga-
rithmic transformation to facilitate clinical interpretation.
Plasma TnI for the Glasgow dataset was measured
using the ARCHITECT STAT Sensitive Troponin-I assay
(limit of detection 0.01 μg/L, coefficient of variation
[CV] 10% at 0.04 μg/L, quoted analytical range 0.00–
50.00 μg/L; Abbott Diagnostics, Lake Forest, IL, USA).
The assay used for the London dataset was the ADVIA
Centaur® TnI-Ultra® three-site sandwich immunoassay
Docherty et al. Critical Care  (2017) 21:216 Page 2 of 10
(Siemens Medical Solutions, Malvern, PA, USA). The
quoted analytical range was 0.006–50 μg/L, total CV
was 2.7–5.3% (measured between 0.08 and 27.2 μg/L),
reference range < 0.039 μg/L. The lower limit for report-
ing was 0.04 μg/L. The assays remained the same
throughout the study periods. We classified TnI <
0.04 μg/L (undetectable) as ‘0 μg/L’; therefore, we added
a small constant (log2[TnI + 0.001]) to all values. We de-
scribe the study cohort stratified by TnI status for ease
of clinical interpretation.
Association of TnI and hospital mortality
We performed univariate logistic regression to assess the
unadjusted association of TnI and hospital mortality,
and we used multivariable logistic regression to assess
the association of TnI and hospital mortality after
adjustment for confounders. For multivariable analyses,
we adjusted for the APACHE II risk prediction model.
To explore potential mechanisms underlying the associ-
ation between TnI and hospital mortality, we assessed
individual components of the APACHE II risk prediction
model: age, chronic health points, emergent surgical
admission, acute physiology score (APS) and APACHE II
diagnosis on ICU admission. We assessed correlation be-
tween TnI and components of the APACHE II model
using the square root of the R2 value (see Additional file 1).
We then adjusted for each component separately for the
relationship between hospital mortality and TnI, and we
compared the impact that each component had on the OR
for hospital mortality by TnI. For details regarding missing
data, see online supplement.
We performed a number of subgroup and sensitivity
analyses for the associations between TnI and hospital
mortality:
1. For routine vs clinical TnI collection, the Glasgow
dataset comprised all TnI samples taken within 24 h of
ICU admission.We compared characteristics and
outcomes of patients who had a TnI sample taken with
routine morning blood laboratory work-up on a
Monday, Wednesday or Friday (‘routine’) with those
who had a TnI work-up done on Tuesday, Thursday,
Saturday or Sunday at clinical discretion (‘clinical’). We
also restricted analyses to patients who had routine
TnI samples taken to explore any bias that might result
from inclusion of clinically indicated TnI samples.
2. We restricted analyses to patients with an APACHE II
comorbidity diagnosis of severe cardiac disease (New
York Heart Association class IV). We hypothesised
that the mechanism of TnI release may be different in
patients with severe cardiovascular disease.
3. We included an interaction term for sex because TnI
release is higher in men than in women, owing to
increased muscle mass of the left ventricle [17].
4. We entered TnI as a binary categorical variable
consistent with diagnostic thresholds for this assay:
‘positive’ (above the limit of reporting, ≥ 0.04) vs
‘negative’ (below the limit of reporting, < 0.04).
Sensitivity analysis
A significant proportion of patients did not have TnI
taken within 24 h of admission. For those patients who
had samples taken at clinical discretion, we believe that
these are ‘missing not at random’, because the mechan-
ism of missingness is likely related to the TnI value.
However, for those samples taken as part of routine care,
we believe that missing values may fulfil criteria to be
‘missing at random’. We therefore imputed the missing
TnI values using multiple imputation by chained equa-
tions to assess the robustness of our analysis for this
subgroup of patients (see online supplement).
Addition of TnI to APACHE II risk prediction model
To explore whether TnI concentration measured during
the first 24 h in ICU added to the risk prediction pro-
perties of the APACHE II, we undertook a derivation
and validation of the model using the datasets with and
without the inclusion of TnI data. For model develop-
ment, we reconstructed the APACHE II risk prediction
model [12] using raw data and derived the predicted
mortality empirically from the multivariable model. We
constructed age points, chronic health points, emer-
gency surgical admission and APS in the same way as
the APACHE II risk prediction model. We modified the
APACHE diagnostic codes by recoding diagnostic codes
with frequency < 10 into ‘other’ disorder for that system
to ensure stability of coefficient estimates. We then
added TnI to the APACHE II model using empirically
weighted coefficients derived from the model. This en-
sured that we did not underestimate any potential con-
tribution to the model from TnI [14].
For model validation, we used the whole Glasgow
dataset to develop the model and applied coefficients
from the development dataset to the London dataset in
line with current guidelines [18]. We reported the per-
formance of the risk prediction model for the following:
calibration, discrimination, AUROC (concordance statis-
tic [c-index], DeLong’s test for two correlated ROC
curves), overall performance score (Brier score) and
overall fit (Akaike information criterion and R2) [18].
We compared how the performance of the APACHE II
risk prediction model was altered by the inclusion of
TnI on the first day in ICU as evidence for early contri-
bution to risk of death.
All data were analysed using the R statistical software
package (version 3.3.2; R Core Team, Vienna, Austria)
[19]. We used the following packages: ggplot2, mfp, rms
and pROC [20–23] (R code; see online supplement).
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Results
Participants
There were 3073 index admissions to GRI between 1
January 2010 and 30 June 2014 (Fig. 1). A total of 1349
patients (43.9%) had TnI taken within 24 h of admission
to ICU (‘Glasgow dataset’). Patients who did not have
TnI taken (n = 1724, 56.1%) were younger, were more
likely to have an elective admission, and had lower APA-
CHE II scores and mortality (ICU, hospital and 6-
month) (Additional file 1: Table S1). The mean age of
patients who had TnI taken within 24 h was 59.6 years
(SD 16.6); 607 (45.0%) were female; and 59.5% were
emergency medical admissions (Table 1). A proportion
of 80.0% had no severe comorbidity (APACHE II score);
the mean APACHE II score was 20.1 (8.1); and median
predicted mortality was 31.7%. Patients with positive TnI
(≥0.04 μg/L) compared with negative TnI (<0.04 μg/L)
were older, and a higher proportion were male, had
emergency medical admissions, had higher APACHE II
scores, and died (in ICU, in hospital and 6-month)
(Table 1). The median TnI in those with a detectable
level (n = 648) was 0.23 μg/L (Q1 0.09, Q3 0.97, max-
imum 69.91).
Association of TnI and hospital mortality
Hospital mortality was 37.3% (n = 242) for TnI-positive
patients compared with 14.6% (n = 102) for TnI-negative
patients (Table 1). There was a significant univariate as-
sociation between TnI as a continuous term and hospital
mortality (Fig. 2a) (OR per doubling of TnI 1.16, 95% CI
1.13–1.20, p < 0.001). This is equivalent to an increase in
predicted hospital mortality from 27.2% to 30.3% if TnI
increases from 0.04 μg/L to 0.08 μg/L and from 42.9% to
46.7% for an increase in TnI from 1.0 μg/L to 2.0 μg/L.
After adjustment for the APACHE II risk prediction
model, TnI remained an independent predictor of
hospital mortality, but the magnitude of prediction was
reduced (Fig. 2b) (OR 1.05, 95% CI 1.01–1.09, p = 0.003).
Correlation of TnI with components of APACHE II model
TnI was most highly correlated with the APS (r = 0.39)
and diagnostic category (r = 0.40) components of the
APACHE II model (Table 2). There was some correl-
ation with age points (r = 0.17) but minimal correlation
with chronic health points (r = 0.11) or emergency sur-
gery (r = 0.10). This was reflected by the impact that
each component had on the association between TnI
and hospital mortality. APS had the greatest impact, re-
ducing the odds of hospital mortality from 1.16 (95% CI
1.13–1.20) to 1.08 (95% CI 1.05–1.11).
Addition of TnI to APACHE II risk prediction model
Derivation
The variables comprising the APACHE II model applied
to this dataset resulted in a c-index of 0.835 (95% CI
0.811–0.858) (Fig. 3), demonstrating good discriminatory
ability and calibration (Additional file 1: Figure S1). The
addition of TnI as a logarithmic term did not improve
the discriminatory power of the model (p = 0.330, c-
index 0.837, 95% CI 0.813–0.860) (Fig. 3), nor did it im-
prove other assessments of model performance (Table 3,
Additional file 1: Figure S2).
Validation
There were 145 patients in the London dataset, which
had demographics similar to the Glasgow dataset (Table 1,
Additional file 1: Table S3). There was a high proportion
of emergency medical admissions (71.0%), with a mean
APACHE II score of 19.1. Hospital mortality was 20.0%.
TnI was significantly associated with hospital mortality
(unadjusted OR TnI 1.23, 95% CI 1.09–1.41). This asso-
ciation was attenuated after adjustment for potential con-
founders (OR 1.16, 95% CI 0.99–1.36).
Fig. 1 Flow of patients through study. GRI Glasgow Royal Infirmary, ICU Intensive care unit, TnI Troponin I
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Applying coefficients derived from the Glasgow data-
derived model, we found a small but statistically signifi-
cant improvement in the c-index after the addition of
TnI; however, CIs were wide (standard APACHE II
model c-index 0.735, 95% CI 0.631–0.845; APACHE II +
TnI c-index 0.752, 95% CI 0.645–0.859; p = 0.010). Other
assessments of model performance showed no improve-
ment with the addition of TnI (Table 3).
Subgroup and sensitivity analyses: multivariate
association of TnI and hospital mortality
Those with a routine TnI sample accounted for 55.3% of
samples taken (n = 746). Those with a TnI sample taken
at clinical discretion accounted for 44.7% (n = 603)
(Additional file 1: Table S1). Clinical group patients were
more likely to be emergency admissions, to have a posi-
tive TnI, to have higher APACHE II scores and predicted
mortality. ICU length of stay, ICU mortality, and hos-
pital or 6-month mortality were similar. Restriction to
routine group patients did not alter the magnitude of
association of TnI in the multivariate model, but the as-
sociation was no longer statistically significant (OR 1.03,
95% CI 0.98–1.09, p = 0.287) (Fig. 4). The OR for TnI in
our sensitivity analysis where we imputed the missing
TnI values in the routine group was 1.04 (95% CI 1.00–
1.08, p = 0.020) (Fig. 2, Additional file 1: Table S2).
TnI was a significant predictor of hospital mortality
when the dataset was restricted to patients (n = 49) with
a diagnosis of severe cardiac disease (OR 1.20, 95% CI
1.00–1.49) (Fig. 4). The odds of hospital mortality were
greater for men (OR 1.08, 95% CI 1.03–1.13) than for
women (OR 1.03, 95% CI 0.98–1.08) (Fig. 4), but this
difference was not significant when tested for interaction
between TnI and sex (p = 0.181) (Additional file 1:
Figure S2). When TnI was entered as a binary variable
‘positive’ (n = 648) vs ‘negative’ (n = 701), the OR of
hospital mortality for positive TnI was 1.43 (95% CI
1.03–1.99) (Fig. 4).
Table 1 Baseline characteristics
Overall % TnI − ve % TnI + ve % p Value
(n = 1349) (n = 701) (n = 648)
Age, years, mean (SD) 59.6 16.6 56.7 16.8 62.8 15.8 < 0.001
Female sex 607 45.0 337 48.1 270 41.7 0.021
Admission type < 0.001
Elective surgery 333 24.7 198 28.2 135 20.8
Emergency surgery 213 15.8 172 24.5 41 6.3
Emergency medical 803 59.5 331 47.2 472 72.8
Deprivation quintile (n = 1143) 0.081
1 (most deprived) 622 46.1 298 42.5 324 50.0
2 193 14.3 108 15.4 85 13.1
3 94 7.0 52 7.4 42 6.5
4 123 9.1 66 9.4 57 8.8
5 (least deprived) 111 8.2 68 9.7 43 6.6
APACHE comorbidities 0.030
0 1079 80.0 589 84.0 490 75.6
1 191 14.2 83 11.7 109 16.8
≥ 2 79 5.9 29 4.1 49 7.6
TnI, μg/L, median [IQR], maximum 0.0 [0.00–0.21], 69.91 – – 0.23 [0.09–0.96], 69.91
Outcomes
ICU mortality 292 21.6 73 10.4 219 33.8 < 0.001
Hospital mortality 344 25.5 102 14.6 242 37.3 < 0.001
6 month mortality 419 31.1 142 20.3 277 42.7 < 0.001
APACHE II predicted mortality, %, median [IQR] 25.3 [9.7–49.7] 17.2 [6.9–32.2] 40.4 [19.8–63.1] < 0.001
APACHE II score, mean (SD) 20.1 8.1 16.9 6.6 23.6 8.1 < 0.001
ICU LOS, median [IQR] 2.9 [1.3–6.8] 2.7 [1.1–6.6] 3.2 [1.6–7.7] < 0.001
Abbreviations: APACHE II Acute Physiological and Chronic Health Evaluation II, ICU Intensive care unit, LOS Length of stay, TnI Troponin I
Stratified by overall population. TnI –ve (<0.04 μg/L) vs TnI + ve (≥0.04 μg/L). p value: test between TnI –ve and TnI + ve: chi-square test/test for trend for categor-
ical variables, t test for parametric continuous variables, Mann-Whitney U test for non-parametric variables. There are no missing data in this table’ patients with
missing TnI values are discussed in the online supplement
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Discussion
In this cohort study of two independent datasets, we
found that an early raised TnI level was associated with
increased mortality in general ICU populations. The
magnitude of the association remained significant but
was markedly attenuated after controlling for other im-
portant predictors of hospital mortality. The addition of
TnI to the APACHE II risk prediction model did not re-
sult in a clinically relevant improvement of model
performance.
Our study has a number of strengths. We had access
to routinely measured TnI in a large, well-defined popu-
lation in the derivation cohort, as well as in a high-
quality validation cohort from a prospective study in a
different population and setting. This contrasts with pre-
vious ICU studies in which researchers have analysed
TnI samples taken for clinical purposes [7, 10]. This
reduced the risk of bias by clinical indication. Although
there have been several large peri-operative studies, this
is the largest study to date to investigate troponin in
ICU patients, allowing subgroup analyses to assess the
robustness of our findings. We used multiple imputation
for missing TnI values in patients who were eligible for
routine TnI sampling. We also used TnI as both a con-
tinuous and a categorical variable. We reported our risk
prediction model to current international best practice
standards, including externally validating the model
rather than internally validating on a proportion of the
derivation cohort [18]. Internally validated prediction
models make use of data only in the development model
and may have an artificially high performance. The ex-
ternal validation dataset provided the heterogeneity that
would be encountered in the real-life application of the
model [14].
Our study has some limitations. Patients who did not
have TnI taken within 24 h of admission to ICU had
Fig. 2 Association between troponin I (TnI; in μg/L) and hospital mortality. a Univariate association (OR per doubling of TnI 1.16, 95% CI 1.13–1.20,
p < 0.001). b Multivariate association between TnI and hospital mortality once added to the Acute Physiological and Chronic Health Evaluation II
model (OR 1.05, 95% CI 1.01–1.09, p < 0.001)
Table 2 Correlation of Acute Physiological and Chronic Health Evaluation II with troponin I
Component of APACHE II Pearson coefficient (r) TnI OR for hospital mortalitya 95% CI
Unadjusted TnI – 1.16 1.13–1.20
Age points 0.17 1.15 1.12–1.19
Chronic health points and emergency surgery 0.11 1.16 1.13–1.19
APS 0.39 1.08 1.05–1.11
Emergency surgery 0.10 1.16 1.12–1.19
Diagnostic category 0.40 1.11 1.07–1.15
Abbreviations: APACHE II Acute Physiological and Chronic Health Evaluation II, APS Acute physiology score component of Acute Physiological and Chronic Health
Evaluation II, TnI Troponin I
Initially, each component was separately added to a univariate analysis with log2(TnI + 0.001) as the dependent variable. The Pearson coefficient (r) is the square
root of the R2 (coefficient of determination) and assesses the correlation between the two variables
aWe adjusted for each component separately for the relationship between hospital mortality and TnI, and we compared the impact that each component had on
the OR for hospital mortality by TnI. Unadjusted OR per doubling TnI: 1.16 (95% CI 1.13–1.20, p < 0.001)
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differences from those who did, which may affect the
generalisability of our findings. This could have occurred
because ICU case mix can differ between certain week-
days and weekends [24, 25] and because patients who
were less sick did not have blood samples taken. Patients
who were eligible for routine TnI sampling but did not
receive it were younger, were less sick and had much
shorter ICU stays. Troponin was reported using the
assays in clinical practice during the study period. The
assays used in the Glasgow and London studies were dif-
ferent, which may have affected interpretation of the
London dataset. Our lower limit of reporting was
0.04 μg/L, which may have resulted in some samples be-
ing classified as ‘0’ μg/L, when TnI may have been de-
tectable using a highly sensitive assay, and this may have
affected women more [17]. We found no significant
interaction between TnI and sex, although our study
may be underpowered for this.
A further limitation was the restriction of troponin
data to the first 24 h of ICU care. This time point is de-
fined by hospital location rather than by illness stage,
and it is therefore potentially subject to lead time bias.
For troponin, this could be particularly relevant, given
the important association between time of symptom on-
set and troponin measurement for maximum diagnostic
value in acute coronary syndrome. This cannot be con-
trolled in ICU populations, but it was a potential source
of variation. We restricted our analyses to the first TnI
taken, but assessing the dynamics of TnI release during
critical illness may have greater prognostic value. In the
future, researchers could explore the dynamics of tropo-
nin release in critically ill patients, which might have a
stronger association with mortality.
The significant univariate association between TnI and
hospital mortality confirms that found in other studies
undertaken in critically ill and high-risk surgical popu-
lations [3–5, 7–9, 26]. In non-cardiac surgical patients,
TnT has also been found to have a significant inde-
pendent association with hospital and longer-term mor-
tality [5, 26]. Both studies made adjustment for patient
characteristics and type of surgery, but they did not in-
clude any measure of acute physiological derangement.
In critically ill patients, Wu et al. found a significant
association between TnI and 6-month mortality after
stratifying by high/low APACHE II scores [8]. Babuin et
al. found that TnT remained a significant predictor of
mortality after adjustment for APACHE III [7]. This was
a retrospective study of patients with a high proportion
of cardiac disease who had TnT measurements taken for
clinical indications. This is consistent with our finding
that, in patients with chronic heart disease, TnI
remained a predictor of mortality after adjustment.
Fig. 3 ROC curves: Acute Physiological and Chronic Health Evaluation
(APACHE) (black solid line; concordance statistic [c-index] 0.847),
APACHE + troponin (red dashed line; c-index 0.846) and troponin I
(green dashed line; c-index 0.696)
Table 3 Model comparison for Glasgow and London datasets (derivation), Acute Physiological and Chronic Health Evaluation II vs
Acute Physiological and Chronic Health Evaluation II + troponin I
Glasgow London
APACHE APACHE + troponin APACHE APACHE + troponin
AUC (95% CI) 0.823 (0.811–0.858) 0.826 (0.813–0.860) 0.737 (0.630–0.845) 0.752 (0.645–0.859)
AIC 1198.0 1188.8 144.5 143.0
R2 0.340 0.349 0.330 0.355
Brier score 0.141 0.140 0.120 0.118
p Value 0.331 0.010
AIC Akaike information criterion, APACHE Acute Physiological and Chronic Health Evaluation
p value: DeLong’s test for two correlated ROC curves. Glasgow model coefficients applied to London dataset (validation)
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Our finding that the association between TnI and
mortality was significant but markedly attenuated after
adjusting for potential confounders suggests that myo-
cardial injury may be on the causal pathway between ill-
ness severity and death: the sicker the patient, the more
troponin is released, and the higher the risk of death.
The causal mechanism of TnI release is unclear. Tropo-
nin release has traditionally been associated with myo-
cardial necrosis and forms a key part of the diagnosis of
MI [1]. However, there is also increasing evidence that
troponin release may occur during myocardial ischaemia
in the absence of myocardial necrosis, potentially due to
shedding of cytosolic troponin [27]. The physiological
stress associated with critical illness may exacerbate oxy-
gen supply-demand imbalance (type II MI) [1, 28], par-
ticularly in those with underlying critical coronary artery
disease. In sepsis, there are profound haemodynamic al-
terations in the microcirculation which may lead to al-
terations in oxygen extraction and tissue oxygenation
[29]. In a minority of critically ill patients, troponin re-
lease may be caused by increased thrombogenicity, lead-
ing to coronary plaque rupture and thrombosis (type I
MI). Proposed non-cardiac mechanisms of troponin re-
lease in the critically ill include direct toxicity from cyto-
kine release, such as tumour necrosis factor-α and
interleukin-6 [30], stretch-mediated troponin release
[30], or ongoing subclinical myocardial injury due to ur-
aemia and impaired excretion [31]. Our datasets did not
allow us to explore in detail underlying mechanisms of
troponin release. However, the APS component repre-
sents acute physiological stress and comprises surrogate
markers of supply (hypoxia, hypotension, anaemia) vs
demand (increased metabolic rate) imbalance, and our
finding that TnI is most strongly correlated with the
APS component of the APACHE II model supports the
hypothesis that myocardial injury may be due to oxygen
supply-demand imbalance. Using Bradford-Hill criteria
for assessing causal relationships, we showed that there
was a biological gradient whereby a greater TnI was as-
sociated with increased mortality, and that there was
consistency across the literature. However, there was no
TnI measurement preceding critical illness, meaning
that we were unable to comment on the temporal asso-
ciation. Furthermore, the strength of association be-
tween TnI and mortality after adjustment for known
confounders was weak, and the mechanism of the asso-
ciation was unclear. This was an observational study,
and unmeasured confounders prevent the inference of
causality. Further exploration would require propensity
or mediation analyses.
Conclusions
We found that the significant association between TnI
and hospital mortality was substantially attenuated after
controlling for potential confounders, particularly acute
physiological derangement. However, the addition of TnI
to the existing APACHE II model did not improve its
performance. Given its relative expense, we would not
advocate the adoption of routine troponin analysis for
general ICU patients on their admission to critical care,
and we would recommend that troponin be measured
only if clinically indicated. Future studies using higher-
generation highly sensitive troponin assays, potentially
exploring changes over time, may further inform the re-
lationship between TnI and mortality.
Fig. 4 Sensitivity and subgroup analyses. OR of hospital mortality for doubling of TnI as a continuous variable for different subgroups after adjusting
for the Acute Physiological and Chronic Health Evaluation II (APACHE II) risk prediction model. ‘Whole cohort categorical’ refers to TnI entered as a
binary variable: TnI + ve vs TnI− ve using the threshold of the limits of detection (0.04). LL Lower limit of 95% CI, UL Upper limit of 95% CI, NYHA New
York Heart Association cardiac disease class IV (APACHE II classification for severe cardiac disease)
Docherty et al. Critical Care  (2017) 21:216 Page 8 of 10
Additional file
Additional file 1: Table S1. Baseline characteristics. Table S2. Baseline
characteristics for patients eligible for routine TnI within 24 h of ICU admission.
Table S3. Baseline characteristics: London dataset. Table S4. Coefficients and
SE for whole dataset. Figure S1. Calibration plot for predicted vs actual
probabilityof hospital mortality. Figure S2. Association of troponin I (in mg/L)
with hospital mortality with interaction term for sex. (DOCX 93 kb)
Abbreviations
AIC: Akaike information criterion; APACHE II: Acute Physiological and Chronic
Health Evaluation II; APS: Acute physiology score component of Acute
Physiological and Chronic Health Evaluation II; c-index: Concordance statistic;
CV: Coefficient of variation; GRI: Glasgow Royal Infirmary; ICU: Intensive care
unit; LL: Lower limit; LOS: Length of stay; MI: Myocardial infarction; NYHA: New
York Heart Association; SICSAG: Scottish Intensive Care Society Audit Group;
SMR01: Scottish Morbidity Record of acute hospital admissions; TnI: Troponin I,
UL, Upper limit; TnT: Troponin T
Acknowledgements
The authors thank Kathryn Henderson and Jennifer McCallum, the Intellispace
Critical Care and Anesthesia information system manager/administrators at NHS
Greater Glasgow and Clyde, and Lorraine Smyth at SICSAG for data extraction
and linkage for this project. The authors also thank Dr. David Treacher, who led
the prospective troponin study in London and approved the collaboration with
the team in Edinburgh, and the research nurses K. Lei, J. Smith and B. Sanderson
for collecting the troponin samples.
Funding
No specific funding was received for this study. Work undertaken as part of
ABD’s doctoral programme was funded by National Blood Service and Scottish
National Blood Transfusion Service.
Availability of data and materials
The datasets used and/or analysed during the present study are available
from the corresponding author on reasonable request.
Authors’ contributions
ABD, MS, JK, TSW and NIL conceived of the study. ABD, MS, MO, MA and JO
performed data collection and data linkage. ABD and NIL performed data
analysis. All authors contributed to data interpretation and manuscript
writing. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All data were anonymised prior to release to the researchers, and therefore
an ethics waiver was granted by the local research ethics committee (West
of Scotland Research Ethics Service, 06/09/15), and approvals from NHS Greater
Glasgow and Clyde Caldicott Guardian (04/06/15) and SICSAG (06/05/15) were
obtained.
Consent for publication
All data were anonymised prior to release to the researchers, and therefore an
ethics waiver for consent was granted by the local research ethics committee.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Anaesthesia, Critical Care and Pain Medicine, University of
Edinburgh, Royal Infirmary Edinburgh, 2nd Floor Anaesthetics Corridor,
Edinburgh EH16 4SA, UK. 2Centre for Inflammation Research, University of
Edinburgh, Edinburgh, UK. 3Academic Unit of Anaesthesia, Pain & Critical
Care, University of Glasgow, Glasgow, UK. 4Department of Critical Care, King’s
College London, Guys and St Thomas’ Hospital, London, UK. 5Internal
Medicine Department, Hospital Jose Joaquim Fernandes, Beja, Portugal.
6Usher Institute of Population Health Sciences and Informatics, University of
Edinburgh, Edinburgh, UK.
Received: 24 April 2017 Accepted: 20 July 2017
References
1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al.
Third universal definition of myocardial infarction. Eur Heart J.
2012;33(20):2551–67.
2. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute
pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–33.
3. Ostermann M, Lo J, Toolan M, Tuddenham E, Sanderson B, Lei K, et al. A
prospective study of the impact of serial troponin measurements on the
diagnosis of myocardial infarction and hospital and six-month mortality in
patients admitted to ICU with non-cardiac diagnoses. Crit Care. 2014;18(2):R62.
4. Lim W, Qushmaq I, Devereaux PJ, Heels-Ansdell D, Lauzier F, Ismaila AS,
et al. Elevated cardiac troponin measurements in critically ill patients. Arch
Intern Med. 2006;166(22):2446–54.
5. Nagele P, Brown F, Gage BF, Gibson DW, Miller JP, Jaffe AS, et al. High-
sensitivity cardiac troponin T in prediction and diagnosis of myocardial
infarction and long-term mortality after noncardiac surgery. Am Heart J.
2013;166(2):325–32. e1.
6. Writing Committee for the VISION Study Investigators. Association of
postoperative high-sensitivity troponin levels with myocardial injury and 30-
day mortality among patients undergoing noncardiac surgery. JAMA. 2017;
317(16):1642–51.
7. Babuin L, Vasile VC, Rio Perez JA, Alegria JR, Chai HS, Afessa B, et al. Elevated
cardiac troponin is an independent risk factor for short- and long-term mortality
in medical intensive care unit patients. Crit Care Med. 2008;36(3):759–65.
8. Wu TT, Yuan A, Chen CY, Chen WJ, Luh KT, Kuo SH, et al. Cardiac troponin I
levels are a risk factor for mortality and multiple organ failure in noncardiac
critically ill patients and have an additive effect to the APACHE II score in
outcome prediction. Shock. 2004;22(2):95–101.
9. King DA, Codish S, Novack V, Barski L, Almog Y. The role of cardiac troponin
I as a prognosticator in critically ill medical patients: a prospective
observational cohort study. Crit Care. 2005;9(4):R390.
10. Lim W, Qushmaq I, Cook DJ, Crowther MA, Heels-Ansdell D, Devereaux PJ,
Troponin T Trials Group. Elevated troponin and myocardial infarction in the
intensive care unit: a prospective study. Crit Care. 2005;9(6):R636.
11. Higgins TL. Quantifying risk and benchmarking performance in the adult
intensive care unit. J Intensive Care Med. 2007;22(3):141–56.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classification system. Crit Care Med. 1985;13(10):818–29.
13. Scottish Intensive Care Society Audit Group (SICSAG). Audit of critical care
in Scotland 2012: reporting on 2011. Edinburgh: ISD Scotland Publications,
Information Services Division, NHS National Services Scotland; 2012.
14. Harrison DA, Ferrando-Vivas P, Shahin J, Rowan KM, editors. Ensuring
comparisons of health-care providers are fair: development and validation
of risk prediction models for critically ill patients. Southampton, UK: NIHR
Journals Library; 2015.
15. Scottish Intensive Care Society Audit Group (SICSAG). Audit of critical care
in Scotland 2015: reporting on 2014. Edinburgh: SICSAG; 2015.
16. Haines R, Crichton S, Wilson J, Treacher D, Ostermann M. Cardiac biomarkers
are associated with maximum stage of acute kidney injury in critically ill
patients: a prospective analysis. Crit Care. 2017;21(1):88.
17. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, et al. High
sensitivity cardiac troponin and the under-diagnosis of myocardial infarction
in women: prospective cohort study. BMJ. 2015;350:g7873.
18. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a
multivariable prediction model for individual prognosis or diagnosis
(TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.
19. R Core Team. R: a language and environment for statistical computing. Vienna,
Austria: R Foundation for Statistical Computing; 2015.
20. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
21. Ambler G, Benner A. mfp: multiple fractional polynomials. R package version
1.5.2. 2015.
22. Harrell FE. rms: regression modeling strategies. R package version 4.5-0. 2016.
23. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an
open-source package for R and S+ to analyze and compare ROC curves.
BMC Bioinformatics. 2011;12:77.
Docherty et al. Critical Care  (2017) 21:216 Page 9 of 10
24. Aldridge C, Bion J, Boyal A, Chen YF, Clancy M, Evans T, et al. Weekend
specialist intensity and admission mortality in acute hospital trusts in
England: a cross-sectional study. Lancet. 2016;388(10040):178–86.
25. Meacock R, Anselmi L, Kristensen SR, Doran T, Sutton M. Higher mortality
rates amongst emergency patients admitted to hospital at weekends reflect
a lower probability of admission. J Health Serv Res Policy. 2017;22(1):12–9.
26. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION)
Study Investigators. Association between postoperative troponin levels and
30-day mortality among patients undergoing noncardiac surgery. JAMA.
2012;307(21):2295–304.
27. Hickman PE, Potter JM, Aroney C, Koerbin G, Southcott E, Wu AH, et al. Cardiac
troponin may be released by ischemia alone, without necrosis. Clin Chim Acta.
2010;411(5-6):318–23.
28. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative
myocardial infarction. Circulation. 2009;119(22):2936–44.
29. De Backer D, Orbegozo Cortes D, Donadello K, Vincent JL. Pathophysiology
of microcirculatory dysfunction and the pathogenesis of septic shock.
Virulence. 2014;5(1):73–9.
30. Ostermann M, Ayis S, Tuddenham E, Lo J, Lei K, Smith J, et al. Cardiac troponin
release is associated with biomarkers of inflammation and ventricular dilatation
during critical illness. Shock. 2017;47(6):702–8.
31. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary
vs. non-coronary disease. Eur Heart J. 2011;32(4):404–11.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Docherty et al. Critical Care  (2017) 21:216 Page 10 of 10
